SlideShare una empresa de Scribd logo
1 de 70
By Dr. Ravikanth Moka
JR/Post Graduate in General Medicine
K.V.G.M.C.H.
Sullia, D.K.
Atrial fibrillation
ECG
Atrial fibrillation
 Atrial fibrillation(AF or A fib), is a
supraventricular arrhythmia characterised
electrocardiographically by low-amplitude
baseline oscillations(fibrillatory or ‘f’ waves)
and an irregularly irregular ventricular rhythm.
 The ‘f’ waves have a rate of 300-600 bpm
and are variable in amplitude, shape and
timing.
 The ventricular rate during Afib typically is
100-160 bpm
Definition
 Atrial fibrillation(AF or A fib), is a
supraventricular arrhythmia characterised
electrocardiographically by low-amplitude
baseline oscillations(fibrillatory or ‘f’ waves)
and an irregularly irregular ventricular rhythm.
 Atrial fibrillation Vs Atrial flutter??
Irregularly irregular R-R intervals
Absent ‘p’ waves
Fibrillatory or ‘f’ waves
Atrial fibrillation
Incidence
 Most common sustained cardiac arrhythmia
 Incidence and prevalence increases with
age
 The incidence
 <0.5% below 50Yrs
 2% in age 60-69
 4.6% in age 70-79
 8.8% in age 80-89
 Men > Women
 Whites > Blacks
Pathophysiology
1. Atrial structural abnormalities
 Disturbance of normal atrial architecture
 Atrial ischemia
 Extra cardiac factors
 Autonomic system
2.Electrophysiological mechanisms
 Multiple wavelet theory
 Automatic focus theory
3. Other pathophysiological mechanisms
Pathophysiology
Pathophysiology
Causes & risk factor a/w Afib
 Mnemonic “PIRATES”:
 Pulmonary embolus, Pulmonary disease, Post-
operative, Pericarditis
 Ischemic heart disease, Idiopathic (“lone atrial
fibrillation”),Intravenous central line (in right atrium)
 Rheumatic valvular disease (specifically mitral stenosis
or mitral regurgitation)
 Anemia, Alcohol (“holiday heart”), Advanced age,
Autonomic tone (vagally mediated Atrial fibrillation)
 Thyroid disease (hyperthyroidism)
 Elevated blood pressure (hypertension), Electrocution
 Sleep apnea, Sepsis.
Causes & risk factor a/w Afib
 Hypertension with LVH, IHD, MVD,
Cardiomyopathies, Constrictive pericarditis,
Cardiac tumours, Pulmonary hypertension
and Diabetes.
 Obesity and Obstructive sleep apnea.
 Temporary causes: Alcohol, Open heart or
thoracic surgery, Myocardial infarction,
Pericarditis, Myocarditis and Pulmonary
embolism.
 Reversible causes: Hyperthyroidism
Terminology Features
1. Paroxysmal AF Spontaneous termination <7 days
2. Persistent AF Not self-terminating lasting >7 days
3. Long standing AF Persistent AF for >1 year
4. Permanent AF Long standing AF refractory to
cardioversion
5. Lone AF Occurs in age group <60 years with
no H/o HTN/Heart disease
6. Nonvalvular AF Absence of rheumatic mitral
stenosis, a mechanical or
bioprosthetic heart valve, or mitral
valve repair
Classification
1. Vagotonic AF
2. Adrenergic AF
Classification
Paroxysmal AF:
Clinical features
Clinical features
 Hallmark of AF on physical examination:
Irregularly irregular pulse.
 Short R-R intervals lead to low LV diastolic filling,
low stroke volume and absence of peripheral
pulses which results in “pulse deficit.”
 Other findings: Irregular jugular venous pulsations
and variable intensity of first heart sound.
Complications
 Stroke
 Heart failure
Stroke with A Fib
Stroke risk:
Without AF
< 60 yrs : 0.5%
> 80 yrs : 3 yrs
With AF
< 60 yrs : 3%
> 80 yrs : 30%
Stroke with A Fib
Stroke with A Fib
Blood stasis
Abnormal
blood
constituents
Left atrium
thrombus
To carotid artery
Anatomical
and structural
defects
Diagnostic evaluation
 Clinical history and Physical examination
 ECG
 Holter monitoring
 Stress test
 ECHO
 Chest radiograph
 Blood tests
ECG
‘p’ waves are absent and R-R interval is variable.
Absent ‘p’ waves are replaced by small irregular oscillations,
called ‘f’ waves(f waves 350-600 beats /min).
ventricular response is grossly irregular at 100-160 beats /min.
Rate : No. of R waves x 10 ( 6 sec strip)
DDX
 Atrial fibrillation Vs Atrial flutter/ MAT/ AVNRT/
NSR with multiple PAC’S ??
Definition A Fib
Atrial
Flutter
MAT
AVNRT
NSR with
Multiple
PAC’S
Atrial flutter
Holter monitoring
Stress test
Echo
Approach to A Fib
 Type of Afib
 Complete history
 Symptoms
 ?Structural heart disease
 Exclude CAD
 Identify correctable Secondary/Reversible
causes
 Develop a treatment strategy
Strategies for treating Atrialfibrillation
 Rhythm control (including cardioversion)
OR
 Rate control
PLUS
 Thromboembolic risk prevention:
based on CHA2DS2-VAS2C score
Acute management
 For hemodynamically unstable patients:
 Sedate if possible and perform an immediate cardioversion.
 If refractory to cardioversion, use IV amiodarone, ibutilide, or
procainamide.
 For hemodynamically stable patients:
 Initiate anticoagulation and rate control.
 If first occurrence, consider cardioversion after adequate
anticoagulation (4 weeks) or no clot seen on TEE and therapeutic
anticoagulation initiated.
 With recurrence, consider referral to an electrophysiologist.
 Consider admission if history suggests a precipitating event (e.g.,
acute MI, PE, HF, etc.).
 Rule out secondary causes based on history.
 Perform complete evaluation.
Rhythm and rate control approaches
 Rhythm control
 Cardioversion (electrical or pharmacological)
 Pharmacological agents (Class IC and III
antiarrhythmics)
 Surgery (maze procedure, ablation)
 Device implantation (pacemaker)
 Rate control
 Pharmacological agents (AV node blockers)
 Surgery with device implantation (ablation plus
pacemaker insertion)
Rate control medications
 -Metoprolol / Esmolol: IV or Oral
 -Diltiazem: IV or Oral
 -Verapamil: Oral Only
 -Digoxin: Patients with hypotension
 -Amiodarone: Also for rhythm control
Rhythm control
Synchronized DC cardioversion
 -Emergencies/Hemodynamic instability
 -Greater efficacy than medications
Pharmacologic cardioversion
 -If AF < 7days –dofetilide, flecainide, ibutilide,
propaferone or amiodarone
 -If AF > 7 day –dofetilide or amiodarone
Rhythm control
Synchronized DC cardioversion
 -Emergencies/Hemodynamic instability
 -Greater efficacy than medications
Pharmacologic cardioversion
 -If AF < 7days –dofetilide, flecainide, ibutilide,
propaferone or amiodarone
 -If AF > 7 day –dofetilide or amiodarone
Rate control as preferred therapy
 Age > 65, less symptomatic,
hypertension
 Recurrent afib
 Previous antiarrhythmic drug failure
 Unlikely to maintain sinus rhythm
(enlarged LA)
Dosage for Rate Control of
AF Beta blockers
Rhythm control as preferred therapy
 ? First episode afib
 Reversible cause (alcohol)
 Symptomatic patient despite rate control
 Patient unable to take anticoagulant (falls,
bleeding, noncompliance)
 CHF precipitated or worsened by afib
 ? Young afib patient (to avoid chronic
electrical and anatomic remodeling that
occurs with afib)
Dosage for Rate Control of
AF Beta blockers
ATRIAL FIBRILLATION 2016
Pace makers/IAD
Ablation
Thrombo-embolic Risk and Treatment
Risk Based Antithrombotic Therapy
 CHA2DS2-VASc score recommended to
assess stroke risk (Class I)
How do we determine stroke risk ?
 0 points – low risk (1.2-3.0 strokes per 100
patient years)
 1-2 points – moderate risk (2.8-4.0 strokes
per 100 patient years)
 > 3 points – high risk (5.9-18.2 strokes per
100 patient years)
Thrombo-embolic Risk and Treatment
Risk Based Antithrombotic Therapy
Contd…
 With prior stroke, TIA, or CHA2DS2-VASc
score ≥2, oral anticoagulants recommended.
Options include:
 Warfarin
 Dabigatran, rivaroxaban, or apixaban (Class I)
 With nonvalvular AF and CHA2DS2-VASc
score of 0, it is reasonable to omit
antithrombotic therapy (Class IIa)
Thrombo-embolic Risk and Treatment
Risk Based Antithrombotic Therapy
 With CHA2DS2-VASc score ≥2 and end-stage
CKD (CrCl <15 mL/min) or on hemodialysis, it
is reasonable to prescribe warfarin for oral
anticoagulation (Class IIa)
 With nonvalvular AF and a CHA2DS2-VASc
score of 1, no antithrombotic therapy or
treatment with oral anticoagulant or aspirin
may be considered (Class IIb)
 After coronary revascularization in patients
with CHA2DS2-VASc score ≥2, it may be
reasonable to use clopidogrel concurrently
with oral anticoagulants but without aspirin
(Class IIb)
Management
 Acute management
 Long term management
Bleeding Risk Accessment
• Assessment of bleeding risk should be
part of the clinical assessment of AF
patients prior to starting anticoagulation
• Antithrombotic benefits and potential
bleeding risks of long-term coagulation
should be explained and discussed with
the patient
• Aim for a target INR of between 2.0 and
3.0
• HAS-BLED Score
Bleeding Risk Accessment(HAS-BLED Score)
Points
 Hypertension (> 160 mm Hg systolic) 1
 Abnormal renal or hepatic function 1-2
 Stroke 1
 Bleeding history or anemia 1
 Labile INR (TTR < 60%) 1
 Elderly (age > 75 years) 1
 Drugs (antiplatelet, NSAID) or alcohol 1-2
 High risk (> 4%/year)>4
 Moderate risk(2-4%/year)2-3
 Low risk(< 2%.year)0-1
ATRIAL FIBRILLATION 2016
Novel oral anticoagulants
Dabigatran
 Oral direct thrombin inhibitor
 Twice daily dosing
 Renal clearance
Rivaroxaban
 Direct factor Xainhibitor
 Once daily (maintenance), twice daily (loading)
 Renal clearance
Apixaban
 Direct factor Xainhibitor
 Twice daily dosing
 Hepatic clearance
Edoxaban
 Direct factor Xainhibitor
 Once daily dosing
 Hepatic clearance
Prevention of Thromboembolism
 With AF or atrial flutter for ≥48 h, or unknown duration,
anticoagulate with warfarin for at least 3 wk before and 4
wk after cardioversion (Class I)
 With AF or atrial flutter for >48 h or unknown duration,
requiring immediate cardioversion, anticoagulate as soon
as possible and continue for at least 4 wk (Class I)
 With AF or atrial flutter <48 h and high stroke risk, IV
heparin or LMWH, or factor Xa or direct thrombin inhibitor,
is recommended before or immediately after
cardioversion, followed by long-term anticoagulation
(Class I)
 With AF or atrial flutter <48 h and low thromboembolic
risk, IV heparin, LMWH, a new oral anticoagulant, or no
antithrombotic may be considered for cardioversion
(Class IIb)
Rate Control guidelines(AHA)
 Control ventricular rate using a beta blocker or non-
DHP CCBs for paroxysmal, persistent, or permanent
AF (Class I)
 IV beta blocker or non-DHP CCBs is recommended
to slow ventricular heart rate in the acute setting in
patients without pre-excitation. In hemodynamically
unstable patients, electrical cardioversion is
indicated (Class I)
 A heart rate control (resting heart rate <80 bpm)
strategy is reasonable for symptomatic management
of AF (Class IIa)
 IV amiodarone can be useful for rate control in
critically ill patients without pre-excitation (Class IIb)
Rate Control guidelines(AHA)
 AV nodal ablation with permanent ventricular pacing
is reasonable when pharmacological therapy is
inadequate and rhythm control is not achievable
(Class IIa)
 A lenient rate-control strategy (resting heart rate
<110 bpm) may be reasonable when patients
remain asymptomatic and LV systolic function is
preserved (Class IIb)
 Non-DHP CCBs should not be used in
decompensated HF (Class III)
 With pre-excitation and AF, digoxin, Non-DHP
CCBs , or amiodarone should not be administered
(Class III)
Restoration of Sinus Rhythm
guidelines(AHA)
Principles of Cardioversion:
 CV may be achieved by means of a drug or an electrical shock.
 Direct-current CV is more effective than pharmacological CV.
 The more recent the onset of AF, the more effective is
pharmacological CV.
 The primary disadvantage of electrical CV is that it requires
sedation or anesthesia.
 The primary disadvantage of pharmacological CV is the risk of
ventricular proarrhythmia.
 The risk of thromboembolism or stroke does not differ between
pharmacological and electrical CV.
 Significant sinus bradycardia after CV can occur in patients on high-
dose AV nodal blocking drugs.
 Antiarrhythmic drug therapy may be administrated prior to CV to
facilitate long-term success and maintenance of normal sinus
rhythm.
Restoration of Sinus Rhythm
guidelines(AHA)
Direct Current Cardioversion:
 Shocks should be delivered synchronous to the R-wave.
 The use of a biphasic defibrillator should be considered with
150-200 joules as the initial energy setting.
 When a rapid ventricular response does not respond
promptly to pharmacological measures for AF patients with
ongoing myocardial ischemia, symptomatic hypotension,
angina, or HF, immediate CV is recommended.
 In case of early relapse of AF after CV, repeated direct-
current CV attempts may be made following administration of
antiarrhythmic medication.
 Electrical CV is contraindicated in patients with digitalis
toxicity or hypokalemia.
Restoration of Sinus Rhythm
guidelines(AHA)
Pharmacological Cardioversion:
 IV ibutilide is an effective drug available to convert AF.
Due to its risk of torsades de pointes, ibutilide should be
avoided in patients with severe systolic dysfunction or a
prolonged QTc (>480 ms).
 More effective for conversion of atrial flutter than of AF;
more effective in cases of more recent onset.
 Can also be used to facilitate electrical CV when it is
unsuccessful, or when there is an immediate recurrence
of AF after initially successful CV.
 Consider IV magnesium (2 grams) prior to giving
ibutilide to reduce risk of torsades de pointes.
 ECG monitoring must be performed for 4 hours after
administration.
Restoration of Sinus Rhythm
guidelines(AHA)
Pharmacological Cardioversion:
 Flecainide and Propafenone
 Both flecainide and propafenone have been studied for
their use as a “pill-in-the pocket” approach to
cardioverting AF.
 Generally, a beta blocker or a calcium channel blocker
should be taken an hour prior to taking the
antiarrhythmic drug when trying to convert AF to SR. For
a person >70 Kg, 300 mg of flecainide or 600 mg of
propafenone should be administered. For <70 Kg, the
dose for flecainide and propafenone is 200 mg and 450
mg, respectively. After administration of the drug, heart
rhythm must be monitored for at least 4-8 hours.
Maintenance of Sinus Rhythm
guidelines(AHA)
Principles of Antiarrhythmic Drug Therapy(AAD):
 Pharmacological therapy to maintain SR is indicated in
patients who have troublesome symptoms related to
paroxysmal AF or recurrent AF after CV who can
tolerate antiarrhythmic drugs (AADs) and have a good
chance of remaining in SR.
 AAD choice is based on side effect profiles and the
presence or absence of structural heart disease, HF,
and hypertension (see flow diagram).
 Drug choice should be individualized and must account
for underlying renal and hepatic function.
 Goals of drug therapy are to decrease the frequency
and duration of episodes, and to improve symptoms.
Maintenance of Sinus Rhythm
guidelines(AHA)
Principles of Antiarrhythmic Drug Therapy:
 AF recurrence while taking an AAD is not indicative of
treatment failure and does not necessitate a change in
antiarrhythmic therapy.
 An AAD should be abandoned when it does not result in
symptomatic improvement or causes adverse effects.
 Ensure normal electrolyte status and appropriate
anticoagulation prior to starting AAD therapy.
 Initiate AV nodal blockade prior to use of an AAD (e.g.
flecainide) that does not provide substantial AV node
blockade.
 Initiate therapy at low dose and titrate up as needed and
after evaluating drug effects on ECG parameters.
AF complicating ACS
 Urgent cardioversion of new-onset AF in the setting of ACS is
recommended for patients with hemodynamic compromise,
ongoing ischemia, or inadequate rate control (Class I)
 IV beta blockers are recommended to slow RVR with ACS and no
HF, hemodynamic instability, or bronchospasm (Class I)
 With ACS and AF with CHA2DS2-VASc score ≥2, anticoagulation
with warfarin is recommended unless contraindicated (Class I)
 Amiodarone or digoxin may be considered to slow RVR with ACS
and AF and severe LV dysfunction and HF or hemodynamic
instability (Class IIb)
 Non-DHP CCBs might be considered to slow RVR with ACS and
AF only in the absence of significant HF or hemodynamic
instability (Class IIb)
Hyperthyroidism
 Beta blockers are recommended to
control ventricular rate with AF
complicating thyrotoxicosis unless
contraindicated (Class I)
 When beta blockers cannot be used, a
Non-DHP CCBs is recommended to
control ventricular rate (Class I)
Pulmonary diseases
 Non-DHP CCBs is recommended to
control ventricular rate with AF and
COPD (Class I)
 Cardioversion should be attempted for
patients with pulmonary disease who
become hemodynamically unstable with
new-onset AF (Class I)
WPW and pre-excitation syndromes
 Cardioversion is recommended for patients with
AF, WPW syndrome who are hemodynamically
compromised (Class I)
 IV procainamide or ibutilide to restore sinus
rhythm or slow ventricular rate is (Class I)
recommended for patients with pre-excited AF
who are not hemodynamically compromised
(Class I)
 IV amiodarone, adenosine, digoxin, or non-DHP
CCBs in patients with WPW syndrome who
have pre-excited AF is potentially harmful
(Class III)
AF during pregnancy
 Digoxin, a beta blocker, or a nondihydropyridine
calcium channel antagonists are recommended
for rate control.
 Direct cardioversion if there is hemodynamic
instability
 Except in patients with low risk profile, either
aspirin or an anticoagulant is recommended for
prevention of thromboembolic complications.
 Unfractionated or LMWH in 1st & last trimester,
oral anticoagulant in 2nd trimester for high risk
group.
 Quinidine or procainamide for pharmacologic
cardioversion in stable patients.
Heart failure
 A beta blocker or non-DHP CCB is
recommended for persistent or permanent AF in
patients with HFpEF (Class I)
 In the absence of preexcitation, an IV beta
blocker (or a non-DHP CCB with HFpEF) is
recommended to slow ventricular response to
AF in the acute setting, with caution in patients
with overt congestion, hypotension, or HFrEF
(Class I)
 In the absence of pre-excitation, IV digoxin or
amiodarone is recommended to control heart
rate acutely (Class I)
 Digoxin is effective to control resting heart rate
with HFrEF (Class I)
Heart failure
 IV amiodarone can be useful to control heart rate with
AF when other measures are unsuccessful or
contraindicated (Class IIa)
 In patients with chronic HF who remain symptomatic
from AF despite a rate-control strategy, it is reasonable
to use a rhythm-control strategy (Class IIa)
 Amiodarone may be considered when resting and
exercise heart rate cannot be controlled with a beta
blocker (or a non-DHP CCB with HFpEF) or digoxin,
alone or in combination (Class IIb)
 For rate control, IV non-DHP CCB, IV beta blockers, and
dronedarone should not be given with decompensated
HF (Class III)
How Can Atrial Fibrillation Be
Prevented?
 Following a healthy lifestyle and taking steps
to lower your risk for heart disease may help
you prevent atrial fibrillation (AF). These
steps include:
 Following a heart healthy diet that's low in
saturated fat, trans fat, and cholesterol. A
healthy diet includes a variety of whole
grains, fruits, and vegetables daily.
 Not smoking.
 Being physically active.
 Maintaining a healthy weight.
 If already having heart disease or other AF
risk factors, regular checkup and followup. In
addition to adopting the healthy habits
above:
 Advise DASH eating plan to help lower blood
pressure.
 Keep cholesterol and triglycerides at healthy
levels with dietary changes and medicines (if
prescribed).
 Limit or avoid alcohol.
 Control of blood sugar level if diabetic.
 Medical care and medicines as prescribed.
Summary
 Most common cardiac arrhythmia
 High prevalence
 Stroke and Heart failure – Risk
 Treatable disease with early and proper
interventions.
Questions?
.
THANK YOU FOR
YOUR PATIENCE
ravikanth.moka@gmail.com
References:
Braunwald’s
American Heart Association guidelines

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Supraventricular tachycardias
Supraventricular tachycardiasSupraventricular tachycardias
Supraventricular tachycardias
 
Atrial fibrillation
Atrial  fibrillation Atrial  fibrillation
Atrial fibrillation
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
Current management of atrial fibrillation
Current management of atrial fibrillationCurrent management of atrial fibrillation
Current management of atrial fibrillation
 
Atrial Fibrillation-Detection and management
Atrial Fibrillation-Detection and managementAtrial Fibrillation-Detection and management
Atrial Fibrillation-Detection and management
 
Supraventricular tachyarrythmias
Supraventricular tachyarrythmiasSupraventricular tachyarrythmias
Supraventricular tachyarrythmias
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
Atrial fibrillation
Atrial fibrillation Atrial fibrillation
Atrial fibrillation
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
Atrial fibrillation & Atrial flutter
Atrial fibrillation & Atrial flutterAtrial fibrillation & Atrial flutter
Atrial fibrillation & Atrial flutter
 
Supraventricular tacchycardias
Supraventricular tacchycardias Supraventricular tacchycardias
Supraventricular tacchycardias
 
Atrial fibrillation (arrhythmia)
Atrial fibrillation (arrhythmia)Atrial fibrillation (arrhythmia)
Atrial fibrillation (arrhythmia)
 
HOCM Hypertrophic cardiomyopathy
HOCM Hypertrophic cardiomyopathyHOCM Hypertrophic cardiomyopathy
HOCM Hypertrophic cardiomyopathy
 
Atrial fib & flutter
Atrial fib & flutterAtrial fib & flutter
Atrial fib & flutter
 
Tachyarrhythmias
TachyarrhythmiasTachyarrhythmias
Tachyarrhythmias
 
HF update 2021
HF update 2021HF update 2021
HF update 2021
 
Ventricular tachycardia
Ventricular tachycardiaVentricular tachycardia
Ventricular tachycardia
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
Atrial fibrillation
Atrial  fibrillation Atrial  fibrillation
Atrial fibrillation
 
Atrial fibrillation
Atrial fibrillation Atrial fibrillation
Atrial fibrillation
 

Similar a ATRIAL FIBRILLATION 2016

Supra ventricular tachycardia
Supra ventricular tachycardiaSupra ventricular tachycardia
Supra ventricular tachycardiaTamil Mani
 
Atrial tachy 26 Oct 22.pptx
Atrial tachy 26 Oct 22.pptxAtrial tachy 26 Oct 22.pptx
Atrial tachy 26 Oct 22.pptxBest Doctors
 
Tachyarrythmias.pptx
Tachyarrythmias.pptxTachyarrythmias.pptx
Tachyarrythmias.pptxHibaMohamed9
 
Management of Atrial Fibrillation Science:Myths & Fashion
Management of Atrial Fibrillation Science:Myths & FashionManagement of Atrial Fibrillation Science:Myths & Fashion
Management of Atrial Fibrillation Science:Myths & Fashiontheheartofthematter
 
MANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptxMANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptxJagtishViramuthu
 
Atrial fibrillation 2014
Atrial fibrillation 2014Atrial fibrillation 2014
Atrial fibrillation 2014johnhakim
 
Cardiac rhythm disturbance
Cardiac rhythm disturbanceCardiac rhythm disturbance
Cardiac rhythm disturbancecardilogy
 
ATRIAL FIBULLATION.pptx
ATRIAL  FIBULLATION.pptxATRIAL  FIBULLATION.pptx
ATRIAL FIBULLATION.pptxAsmauBelko
 
Atrial Fibrillation - BMH/Tele
Atrial Fibrillation - BMH/TeleAtrial Fibrillation - BMH/Tele
Atrial Fibrillation - BMH/TeleTeleClinEd
 
Samir rafla ecg arrhythmia for medical students- added amr kamal
Samir rafla  ecg arrhythmia for medical students- added amr kamalSamir rafla  ecg arrhythmia for medical students- added amr kamal
Samir rafla ecg arrhythmia for medical students- added amr kamalSamirRafla1
 
Artrial fibrillation classification & management guideline
Artrial fibrillation classification & management guidelineArtrial fibrillation classification & management guideline
Artrial fibrillation classification & management guidelineDr. Rohan Sonawane
 
2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelinespurplevivid
 

Similar a ATRIAL FIBRILLATION 2016 (20)

Supra ventricular tachycardia
Supra ventricular tachycardiaSupra ventricular tachycardia
Supra ventricular tachycardia
 
af afl ppt, Virbhan
af afl ppt, Virbhanaf afl ppt, Virbhan
af afl ppt, Virbhan
 
ecg
ecgecg
ecg
 
Atrial tachy 26 Oct 22.pptx
Atrial tachy 26 Oct 22.pptxAtrial tachy 26 Oct 22.pptx
Atrial tachy 26 Oct 22.pptx
 
atrial fibrallition.ppt
atrial fibrallition.pptatrial fibrallition.ppt
atrial fibrallition.ppt
 
Samir Rafla - ECG arrhythmia for medical students
Samir Rafla - ECG arrhythmia for medical studentsSamir Rafla - ECG arrhythmia for medical students
Samir Rafla - ECG arrhythmia for medical students
 
Tachyarrythmias.pptx
Tachyarrythmias.pptxTachyarrythmias.pptx
Tachyarrythmias.pptx
 
Management of Atrial Fibrillation Science:Myths & Fashion
Management of Atrial Fibrillation Science:Myths & FashionManagement of Atrial Fibrillation Science:Myths & Fashion
Management of Atrial Fibrillation Science:Myths & Fashion
 
MANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptxMANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptx
 
Atrial Fibrillation
Atrial FibrillationAtrial Fibrillation
Atrial Fibrillation
 
Atrial fibrillation 2014
Atrial fibrillation 2014Atrial fibrillation 2014
Atrial fibrillation 2014
 
Cardiac rhythm disturbance
Cardiac rhythm disturbanceCardiac rhythm disturbance
Cardiac rhythm disturbance
 
ATRIAL FIBULLATION.pptx
ATRIAL  FIBULLATION.pptxATRIAL  FIBULLATION.pptx
ATRIAL FIBULLATION.pptx
 
Atrial Fibrillation - BMH/Tele
Atrial Fibrillation - BMH/TeleAtrial Fibrillation - BMH/Tele
Atrial Fibrillation - BMH/Tele
 
Samir rafla ecg arrhythmia for medical students- added amr kamal
Samir rafla  ecg arrhythmia for medical students- added amr kamalSamir rafla  ecg arrhythmia for medical students- added amr kamal
Samir rafla ecg arrhythmia for medical students- added amr kamal
 
Artrial fibrillation classification & management guideline
Artrial fibrillation classification & management guidelineArtrial fibrillation classification & management guideline
Artrial fibrillation classification & management guideline
 
Atrial Fibrillation 2016
Atrial Fibrillation 2016Atrial Fibrillation 2016
Atrial Fibrillation 2016
 
ARRYTHMIA.pptx
ARRYTHMIA.pptxARRYTHMIA.pptx
ARRYTHMIA.pptx
 
2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines2014 AHA/ACC Atrial Fibrillation Guidelines
2014 AHA/ACC Atrial Fibrillation Guidelines
 
Atrial fibrillation (af)
Atrial fibrillation (af)Atrial fibrillation (af)
Atrial fibrillation (af)
 

Último

CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 

Último (20)

CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 

ATRIAL FIBRILLATION 2016

  • 1. By Dr. Ravikanth Moka JR/Post Graduate in General Medicine K.V.G.M.C.H. Sullia, D.K.
  • 3. ECG
  • 4. Atrial fibrillation  Atrial fibrillation(AF or A fib), is a supraventricular arrhythmia characterised electrocardiographically by low-amplitude baseline oscillations(fibrillatory or ‘f’ waves) and an irregularly irregular ventricular rhythm.  The ‘f’ waves have a rate of 300-600 bpm and are variable in amplitude, shape and timing.  The ventricular rate during Afib typically is 100-160 bpm
  • 5. Definition  Atrial fibrillation(AF or A fib), is a supraventricular arrhythmia characterised electrocardiographically by low-amplitude baseline oscillations(fibrillatory or ‘f’ waves) and an irregularly irregular ventricular rhythm.  Atrial fibrillation Vs Atrial flutter?? Irregularly irregular R-R intervals Absent ‘p’ waves Fibrillatory or ‘f’ waves Atrial fibrillation
  • 6. Incidence  Most common sustained cardiac arrhythmia  Incidence and prevalence increases with age  The incidence  <0.5% below 50Yrs  2% in age 60-69  4.6% in age 70-79  8.8% in age 80-89  Men > Women  Whites > Blacks
  • 7. Pathophysiology 1. Atrial structural abnormalities  Disturbance of normal atrial architecture  Atrial ischemia  Extra cardiac factors  Autonomic system 2.Electrophysiological mechanisms  Multiple wavelet theory  Automatic focus theory 3. Other pathophysiological mechanisms
  • 10. Causes & risk factor a/w Afib  Mnemonic “PIRATES”:  Pulmonary embolus, Pulmonary disease, Post- operative, Pericarditis  Ischemic heart disease, Idiopathic (“lone atrial fibrillation”),Intravenous central line (in right atrium)  Rheumatic valvular disease (specifically mitral stenosis or mitral regurgitation)  Anemia, Alcohol (“holiday heart”), Advanced age, Autonomic tone (vagally mediated Atrial fibrillation)  Thyroid disease (hyperthyroidism)  Elevated blood pressure (hypertension), Electrocution  Sleep apnea, Sepsis.
  • 11. Causes & risk factor a/w Afib  Hypertension with LVH, IHD, MVD, Cardiomyopathies, Constrictive pericarditis, Cardiac tumours, Pulmonary hypertension and Diabetes.  Obesity and Obstructive sleep apnea.  Temporary causes: Alcohol, Open heart or thoracic surgery, Myocardial infarction, Pericarditis, Myocarditis and Pulmonary embolism.  Reversible causes: Hyperthyroidism
  • 12. Terminology Features 1. Paroxysmal AF Spontaneous termination <7 days 2. Persistent AF Not self-terminating lasting >7 days 3. Long standing AF Persistent AF for >1 year 4. Permanent AF Long standing AF refractory to cardioversion 5. Lone AF Occurs in age group <60 years with no H/o HTN/Heart disease 6. Nonvalvular AF Absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair Classification
  • 13. 1. Vagotonic AF 2. Adrenergic AF Classification Paroxysmal AF:
  • 15. Clinical features  Hallmark of AF on physical examination: Irregularly irregular pulse.  Short R-R intervals lead to low LV diastolic filling, low stroke volume and absence of peripheral pulses which results in “pulse deficit.”  Other findings: Irregular jugular venous pulsations and variable intensity of first heart sound.
  • 17. Stroke with A Fib Stroke risk: Without AF < 60 yrs : 0.5% > 80 yrs : 3 yrs With AF < 60 yrs : 3% > 80 yrs : 30%
  • 19. Stroke with A Fib Blood stasis Abnormal blood constituents Left atrium thrombus To carotid artery Anatomical and structural defects
  • 20. Diagnostic evaluation  Clinical history and Physical examination  ECG  Holter monitoring  Stress test  ECHO  Chest radiograph  Blood tests
  • 21. ECG ‘p’ waves are absent and R-R interval is variable. Absent ‘p’ waves are replaced by small irregular oscillations, called ‘f’ waves(f waves 350-600 beats /min). ventricular response is grossly irregular at 100-160 beats /min. Rate : No. of R waves x 10 ( 6 sec strip)
  • 22. DDX  Atrial fibrillation Vs Atrial flutter/ MAT/ AVNRT/ NSR with multiple PAC’S ??
  • 23. Definition A Fib Atrial Flutter MAT AVNRT NSR with Multiple PAC’S Atrial flutter
  • 26. Echo
  • 27. Approach to A Fib  Type of Afib  Complete history  Symptoms  ?Structural heart disease  Exclude CAD  Identify correctable Secondary/Reversible causes  Develop a treatment strategy
  • 28. Strategies for treating Atrialfibrillation  Rhythm control (including cardioversion) OR  Rate control PLUS  Thromboembolic risk prevention: based on CHA2DS2-VAS2C score
  • 29. Acute management  For hemodynamically unstable patients:  Sedate if possible and perform an immediate cardioversion.  If refractory to cardioversion, use IV amiodarone, ibutilide, or procainamide.  For hemodynamically stable patients:  Initiate anticoagulation and rate control.  If first occurrence, consider cardioversion after adequate anticoagulation (4 weeks) or no clot seen on TEE and therapeutic anticoagulation initiated.  With recurrence, consider referral to an electrophysiologist.  Consider admission if history suggests a precipitating event (e.g., acute MI, PE, HF, etc.).  Rule out secondary causes based on history.  Perform complete evaluation.
  • 30. Rhythm and rate control approaches  Rhythm control  Cardioversion (electrical or pharmacological)  Pharmacological agents (Class IC and III antiarrhythmics)  Surgery (maze procedure, ablation)  Device implantation (pacemaker)  Rate control  Pharmacological agents (AV node blockers)  Surgery with device implantation (ablation plus pacemaker insertion)
  • 31. Rate control medications  -Metoprolol / Esmolol: IV or Oral  -Diltiazem: IV or Oral  -Verapamil: Oral Only  -Digoxin: Patients with hypotension  -Amiodarone: Also for rhythm control
  • 32. Rhythm control Synchronized DC cardioversion  -Emergencies/Hemodynamic instability  -Greater efficacy than medications Pharmacologic cardioversion  -If AF < 7days –dofetilide, flecainide, ibutilide, propaferone or amiodarone  -If AF > 7 day –dofetilide or amiodarone
  • 33. Rhythm control Synchronized DC cardioversion  -Emergencies/Hemodynamic instability  -Greater efficacy than medications Pharmacologic cardioversion  -If AF < 7days –dofetilide, flecainide, ibutilide, propaferone or amiodarone  -If AF > 7 day –dofetilide or amiodarone
  • 34. Rate control as preferred therapy  Age > 65, less symptomatic, hypertension  Recurrent afib  Previous antiarrhythmic drug failure  Unlikely to maintain sinus rhythm (enlarged LA)
  • 35. Dosage for Rate Control of AF Beta blockers
  • 36. Rhythm control as preferred therapy  ? First episode afib  Reversible cause (alcohol)  Symptomatic patient despite rate control  Patient unable to take anticoagulant (falls, bleeding, noncompliance)  CHF precipitated or worsened by afib  ? Young afib patient (to avoid chronic electrical and anatomic remodeling that occurs with afib)
  • 37. Dosage for Rate Control of AF Beta blockers
  • 41. Thrombo-embolic Risk and Treatment Risk Based Antithrombotic Therapy  CHA2DS2-VASc score recommended to assess stroke risk (Class I)
  • 42. How do we determine stroke risk ?  0 points – low risk (1.2-3.0 strokes per 100 patient years)  1-2 points – moderate risk (2.8-4.0 strokes per 100 patient years)  > 3 points – high risk (5.9-18.2 strokes per 100 patient years)
  • 43. Thrombo-embolic Risk and Treatment Risk Based Antithrombotic Therapy Contd…  With prior stroke, TIA, or CHA2DS2-VASc score ≥2, oral anticoagulants recommended. Options include:  Warfarin  Dabigatran, rivaroxaban, or apixaban (Class I)  With nonvalvular AF and CHA2DS2-VASc score of 0, it is reasonable to omit antithrombotic therapy (Class IIa)
  • 44. Thrombo-embolic Risk and Treatment Risk Based Antithrombotic Therapy  With CHA2DS2-VASc score ≥2 and end-stage CKD (CrCl <15 mL/min) or on hemodialysis, it is reasonable to prescribe warfarin for oral anticoagulation (Class IIa)  With nonvalvular AF and a CHA2DS2-VASc score of 1, no antithrombotic therapy or treatment with oral anticoagulant or aspirin may be considered (Class IIb)  After coronary revascularization in patients with CHA2DS2-VASc score ≥2, it may be reasonable to use clopidogrel concurrently with oral anticoagulants but without aspirin (Class IIb)
  • 45. Management  Acute management  Long term management
  • 46. Bleeding Risk Accessment • Assessment of bleeding risk should be part of the clinical assessment of AF patients prior to starting anticoagulation • Antithrombotic benefits and potential bleeding risks of long-term coagulation should be explained and discussed with the patient • Aim for a target INR of between 2.0 and 3.0 • HAS-BLED Score
  • 47. Bleeding Risk Accessment(HAS-BLED Score) Points  Hypertension (> 160 mm Hg systolic) 1  Abnormal renal or hepatic function 1-2  Stroke 1  Bleeding history or anemia 1  Labile INR (TTR < 60%) 1  Elderly (age > 75 years) 1  Drugs (antiplatelet, NSAID) or alcohol 1-2  High risk (> 4%/year)>4  Moderate risk(2-4%/year)2-3  Low risk(< 2%.year)0-1
  • 49. Novel oral anticoagulants Dabigatran  Oral direct thrombin inhibitor  Twice daily dosing  Renal clearance Rivaroxaban  Direct factor Xainhibitor  Once daily (maintenance), twice daily (loading)  Renal clearance Apixaban  Direct factor Xainhibitor  Twice daily dosing  Hepatic clearance Edoxaban  Direct factor Xainhibitor  Once daily dosing  Hepatic clearance
  • 50. Prevention of Thromboembolism  With AF or atrial flutter for ≥48 h, or unknown duration, anticoagulate with warfarin for at least 3 wk before and 4 wk after cardioversion (Class I)  With AF or atrial flutter for >48 h or unknown duration, requiring immediate cardioversion, anticoagulate as soon as possible and continue for at least 4 wk (Class I)  With AF or atrial flutter <48 h and high stroke risk, IV heparin or LMWH, or factor Xa or direct thrombin inhibitor, is recommended before or immediately after cardioversion, followed by long-term anticoagulation (Class I)  With AF or atrial flutter <48 h and low thromboembolic risk, IV heparin, LMWH, a new oral anticoagulant, or no antithrombotic may be considered for cardioversion (Class IIb)
  • 51. Rate Control guidelines(AHA)  Control ventricular rate using a beta blocker or non- DHP CCBs for paroxysmal, persistent, or permanent AF (Class I)  IV beta blocker or non-DHP CCBs is recommended to slow ventricular heart rate in the acute setting in patients without pre-excitation. In hemodynamically unstable patients, electrical cardioversion is indicated (Class I)  A heart rate control (resting heart rate <80 bpm) strategy is reasonable for symptomatic management of AF (Class IIa)  IV amiodarone can be useful for rate control in critically ill patients without pre-excitation (Class IIb)
  • 52. Rate Control guidelines(AHA)  AV nodal ablation with permanent ventricular pacing is reasonable when pharmacological therapy is inadequate and rhythm control is not achievable (Class IIa)  A lenient rate-control strategy (resting heart rate <110 bpm) may be reasonable when patients remain asymptomatic and LV systolic function is preserved (Class IIb)  Non-DHP CCBs should not be used in decompensated HF (Class III)  With pre-excitation and AF, digoxin, Non-DHP CCBs , or amiodarone should not be administered (Class III)
  • 53. Restoration of Sinus Rhythm guidelines(AHA) Principles of Cardioversion:  CV may be achieved by means of a drug or an electrical shock.  Direct-current CV is more effective than pharmacological CV.  The more recent the onset of AF, the more effective is pharmacological CV.  The primary disadvantage of electrical CV is that it requires sedation or anesthesia.  The primary disadvantage of pharmacological CV is the risk of ventricular proarrhythmia.  The risk of thromboembolism or stroke does not differ between pharmacological and electrical CV.  Significant sinus bradycardia after CV can occur in patients on high- dose AV nodal blocking drugs.  Antiarrhythmic drug therapy may be administrated prior to CV to facilitate long-term success and maintenance of normal sinus rhythm.
  • 54. Restoration of Sinus Rhythm guidelines(AHA) Direct Current Cardioversion:  Shocks should be delivered synchronous to the R-wave.  The use of a biphasic defibrillator should be considered with 150-200 joules as the initial energy setting.  When a rapid ventricular response does not respond promptly to pharmacological measures for AF patients with ongoing myocardial ischemia, symptomatic hypotension, angina, or HF, immediate CV is recommended.  In case of early relapse of AF after CV, repeated direct- current CV attempts may be made following administration of antiarrhythmic medication.  Electrical CV is contraindicated in patients with digitalis toxicity or hypokalemia.
  • 55. Restoration of Sinus Rhythm guidelines(AHA) Pharmacological Cardioversion:  IV ibutilide is an effective drug available to convert AF. Due to its risk of torsades de pointes, ibutilide should be avoided in patients with severe systolic dysfunction or a prolonged QTc (>480 ms).  More effective for conversion of atrial flutter than of AF; more effective in cases of more recent onset.  Can also be used to facilitate electrical CV when it is unsuccessful, or when there is an immediate recurrence of AF after initially successful CV.  Consider IV magnesium (2 grams) prior to giving ibutilide to reduce risk of torsades de pointes.  ECG monitoring must be performed for 4 hours after administration.
  • 56. Restoration of Sinus Rhythm guidelines(AHA) Pharmacological Cardioversion:  Flecainide and Propafenone  Both flecainide and propafenone have been studied for their use as a “pill-in-the pocket” approach to cardioverting AF.  Generally, a beta blocker or a calcium channel blocker should be taken an hour prior to taking the antiarrhythmic drug when trying to convert AF to SR. For a person >70 Kg, 300 mg of flecainide or 600 mg of propafenone should be administered. For <70 Kg, the dose for flecainide and propafenone is 200 mg and 450 mg, respectively. After administration of the drug, heart rhythm must be monitored for at least 4-8 hours.
  • 57. Maintenance of Sinus Rhythm guidelines(AHA) Principles of Antiarrhythmic Drug Therapy(AAD):  Pharmacological therapy to maintain SR is indicated in patients who have troublesome symptoms related to paroxysmal AF or recurrent AF after CV who can tolerate antiarrhythmic drugs (AADs) and have a good chance of remaining in SR.  AAD choice is based on side effect profiles and the presence or absence of structural heart disease, HF, and hypertension (see flow diagram).  Drug choice should be individualized and must account for underlying renal and hepatic function.  Goals of drug therapy are to decrease the frequency and duration of episodes, and to improve symptoms.
  • 58. Maintenance of Sinus Rhythm guidelines(AHA) Principles of Antiarrhythmic Drug Therapy:  AF recurrence while taking an AAD is not indicative of treatment failure and does not necessitate a change in antiarrhythmic therapy.  An AAD should be abandoned when it does not result in symptomatic improvement or causes adverse effects.  Ensure normal electrolyte status and appropriate anticoagulation prior to starting AAD therapy.  Initiate AV nodal blockade prior to use of an AAD (e.g. flecainide) that does not provide substantial AV node blockade.  Initiate therapy at low dose and titrate up as needed and after evaluating drug effects on ECG parameters.
  • 59. AF complicating ACS  Urgent cardioversion of new-onset AF in the setting of ACS is recommended for patients with hemodynamic compromise, ongoing ischemia, or inadequate rate control (Class I)  IV beta blockers are recommended to slow RVR with ACS and no HF, hemodynamic instability, or bronchospasm (Class I)  With ACS and AF with CHA2DS2-VASc score ≥2, anticoagulation with warfarin is recommended unless contraindicated (Class I)  Amiodarone or digoxin may be considered to slow RVR with ACS and AF and severe LV dysfunction and HF or hemodynamic instability (Class IIb)  Non-DHP CCBs might be considered to slow RVR with ACS and AF only in the absence of significant HF or hemodynamic instability (Class IIb)
  • 60. Hyperthyroidism  Beta blockers are recommended to control ventricular rate with AF complicating thyrotoxicosis unless contraindicated (Class I)  When beta blockers cannot be used, a Non-DHP CCBs is recommended to control ventricular rate (Class I)
  • 61. Pulmonary diseases  Non-DHP CCBs is recommended to control ventricular rate with AF and COPD (Class I)  Cardioversion should be attempted for patients with pulmonary disease who become hemodynamically unstable with new-onset AF (Class I)
  • 62. WPW and pre-excitation syndromes  Cardioversion is recommended for patients with AF, WPW syndrome who are hemodynamically compromised (Class I)  IV procainamide or ibutilide to restore sinus rhythm or slow ventricular rate is (Class I) recommended for patients with pre-excited AF who are not hemodynamically compromised (Class I)  IV amiodarone, adenosine, digoxin, or non-DHP CCBs in patients with WPW syndrome who have pre-excited AF is potentially harmful (Class III)
  • 63. AF during pregnancy  Digoxin, a beta blocker, or a nondihydropyridine calcium channel antagonists are recommended for rate control.  Direct cardioversion if there is hemodynamic instability  Except in patients with low risk profile, either aspirin or an anticoagulant is recommended for prevention of thromboembolic complications.  Unfractionated or LMWH in 1st & last trimester, oral anticoagulant in 2nd trimester for high risk group.  Quinidine or procainamide for pharmacologic cardioversion in stable patients.
  • 64. Heart failure  A beta blocker or non-DHP CCB is recommended for persistent or permanent AF in patients with HFpEF (Class I)  In the absence of preexcitation, an IV beta blocker (or a non-DHP CCB with HFpEF) is recommended to slow ventricular response to AF in the acute setting, with caution in patients with overt congestion, hypotension, or HFrEF (Class I)  In the absence of pre-excitation, IV digoxin or amiodarone is recommended to control heart rate acutely (Class I)  Digoxin is effective to control resting heart rate with HFrEF (Class I)
  • 65. Heart failure  IV amiodarone can be useful to control heart rate with AF when other measures are unsuccessful or contraindicated (Class IIa)  In patients with chronic HF who remain symptomatic from AF despite a rate-control strategy, it is reasonable to use a rhythm-control strategy (Class IIa)  Amiodarone may be considered when resting and exercise heart rate cannot be controlled with a beta blocker (or a non-DHP CCB with HFpEF) or digoxin, alone or in combination (Class IIb)  For rate control, IV non-DHP CCB, IV beta blockers, and dronedarone should not be given with decompensated HF (Class III)
  • 66. How Can Atrial Fibrillation Be Prevented?  Following a healthy lifestyle and taking steps to lower your risk for heart disease may help you prevent atrial fibrillation (AF). These steps include:  Following a heart healthy diet that's low in saturated fat, trans fat, and cholesterol. A healthy diet includes a variety of whole grains, fruits, and vegetables daily.  Not smoking.  Being physically active.  Maintaining a healthy weight.
  • 67.  If already having heart disease or other AF risk factors, regular checkup and followup. In addition to adopting the healthy habits above:  Advise DASH eating plan to help lower blood pressure.  Keep cholesterol and triglycerides at healthy levels with dietary changes and medicines (if prescribed).  Limit or avoid alcohol.  Control of blood sugar level if diabetic.  Medical care and medicines as prescribed.
  • 68. Summary  Most common cardiac arrhythmia  High prevalence  Stroke and Heart failure – Risk  Treatable disease with early and proper interventions.
  • 70. . THANK YOU FOR YOUR PATIENCE ravikanth.moka@gmail.com References: Braunwald’s American Heart Association guidelines